Tannock, I. F., de Vries, E. G. E., Fojo, A., Buyse, M., & Moja, L. (2025). Dose optimisation to improve access to effective cancer medicines. The Lancet Oncology, 26(3), e171–e180. https://doi.org/10.1016/s1470-2045(24)00648-x

Morris, Z. S., Demaria, S., Monjazeb, A. M., Formenti, S. C., Weichselbaum, R. R., Welsh, J., Enderling, H., Schoenfeld, J. D., Brody, J. D., McGee, H. M., Mondini, M., Kent, M. S., Young, K. H., Galluzzi, L., Karam, S. D., Theelen, W. S. M. E., Chang, J. Y., Huynh, M. A., Daib, A., … Fong, L. (2025). Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation. The Lancet Oncology, 26(3), e152–e170. https://doi.org/10.1016/s1470-2045(24)00656-9

Bazarbachi, A.-H., Magrini, N., Aziz, Z., & Fojo, T. (2025). Evidence for a reduction in number of cycles of immune checkpoint inhibitors. The Lancet Oncology, 26(1), 9–11. https://doi.org/10.1016/s1470-2045(24)00594-1

Ercan, A. B., Aronson, M., Fernandez, N. R., Chang, Y., Levine, A., Liu, Z. A., Negm, L., Edwards, M., Bianchi, V., Stengs, L., Chung, J., Al-Battashi, A., Reschke, A., Lion, A., Ahmad, A., Lassaletta, A., Reddy, A. T., Al-Darraji, A. F., Shah, A. C., … Tabori, U. (2024). Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study. The Lancet Oncology, 25(5), 668–682. https://doi.org/10.1016/s1470-2045(24)00026-3

Mahadeo, K. M., Baiocchi, R., Beitinjaneh, A., Chaganti, S., Choquet, S., Dierickx, D., Dinavahi, R., Duan, X., Gamelin, L., Ghobadi, A., Guzman-Becerra, N., Joshi, M., Mehta, A., Navarro, W. H., Nikiforow, S., O’Reilly, R. J., Reshef, R., Ruiz, F., Spindler, T., & Prockop, S. (2024). Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial. The Lancet Oncology, 25(3), 376–387. https://doi.org/10.1016/s1470-2045(23)00649-6

Ehrlich, M. I., Labadie, B. W., Bates, S. E., & Fojo, T. (2024). Mitotane and the myth of 14 mg/L. The Lancet Oncology, 25(1), 12–15. https://doi.org/10.1016/s1470-2045(23)00537-5

Cytryn, S. L., Moy, R. H., Cowzer, D., Shah, R. H., Chou, J. F., Joshi, S. S., Ku, G. Y., Maron, S. B., Desai, A., Yang, J., Sugarman, R., Rao, D., Goldberg, Z., Charalambous, C., Lapshina, M., Antoine, A., Socolow, F., Trivedi, N., Capanu, M., … Janjigian, Y. Y. (2023). First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial. The Lancet Oncology, 24(10), 1073–1082. https://doi.org/10.1016/s1470-2045(23)00358-3

Chidebe, R. C. W., Leibel, L. L., Orjiakor, T. C., Shrestha, A., Agha, A. A., Altinok Dindar, D., Kisakol, B., Ipiankama, S. C., Okoye, I. J., Mason, M., Auguste, A., & Esiaka, D. K. (2023). Promoting cancer prevention through World Cancer Day in Nigeria. The Lancet Oncology, 24(4), 319–322. https://doi.org/10.1016/s1470-2045(22)00692-1

Spinazzi, E. F., Argenziano, M. G., Upadhyayula, P. S., Banu, M. A., Neira, J. A., Higgins, D. M. O., Wu, P. B., Pereira, B., Mahajan, A., Humala, N., Al-Dalahmah, O., Zhao, W., Save, A. V., Gill, B. J. A., Boyett, D. M., Marie, T., Furnari, J. L., Sudhakar, T. D., Stopka, S. A., … Bruce, J. N. (2022). Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: a first-in-patient, single-centre, single-arm, phase 1b trial. The Lancet Oncology, 23(11), 1409–1418. https://doi.org/10.1016/s1470-2045(22)00599-x

Shi, D. D., Guo, J. A., Hoffman, H. I., Su, J., Mino-Kenudson, M., Barth, J. L., Schenkel, J. M., Loeffler, J. S., Shih, H. A., Hong, T. S., Wo, J. Y., Aguirre, A. J., Jacks, T., Zheng, L., Wen, P. Y., Wang, T. C., & Hwang, W. L. (2022). Therapeutic avenues for cancer neuroscience: translational frontiers and clinical opportunities. The Lancet Oncology, 23(2), e62–e74. https://doi.org/10.1016/s1470-2045(21)00596-9

Safran, H. P., Winter, K., Ilson, D. H., Wigle, D., DiPetrillo, T., Haddock, M. G., Hong, T. S., Leichman, L. P., Rajdev, L., Resnick, M., Kachnic, L. A., Seaward, S., Mamon, H., Diaz Pardo, D. A., Anderson, C. M., Shen, X., Sharma, A. K., Katz, A. W., Salo, J., … Crane, C. H. (2022). Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial. The Lancet Oncology, 23(2), 259–269. https://doi.org/10.1016/s1470-2045(21)00718-x

Jacobson, C. A., Chavez, J. C., Sehgal, A. R., William, B. M., Munoz, J., Salles, G., Munshi, P. N., Casulo, C., Maloney, D. G., de Vos, S., Reshef, R., Leslie, L. A., Yakoub-Agha, I., Oluwole, O. O., Fung, H. C. H., Rosenblatt, J., Rossi, J. M., Goyal, L., Plaks, V., … Neelapu, S. S. (2022). Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. The Lancet Oncology, 23(1), 91–103. https://doi.org/10.1016/s1470-2045(21)00591-x